Stay updated with breaking news from Christopher Cutie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson announced on Friday encouraging results from a Phase 2b study evaluating the efficacy and safety of the investigational monotherapy TAR-200 in patients with BCG-naive high-risk...
/PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of...
Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, […]
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study...